RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Aiming, Dr. Stoll hasn't said anything new about an interim analysis. He'll probably give an update on all the trials at the R+R Conf next week.

Peregrine does look interesting, though they have less cash than Cortex (~16 mil), and they have a ton of shares outstanding (~ 170 mil or so). The share price is only a dollar, but the market cap is already somewhat high due to all the outstanding shares. Looks like they're probably going to have to raise some money soon. The idea of a monoclonal antibody attacking the abnormally positioned cell wall lipids associated with tumor vasculature makes some sense, but I'll have to research into how the same compound also works against viruses. That program looks very early stage, so I don't see how it could impact the avian flu problem in the near term. I'll have to check them out more thoroughly though. I wonder if Dew has an opinion on the stock?